AngioDynamics Announces the Release of New 65cm ELVS Procedure Kit.Business Editors/Health/Medical Writers QUEENSBURY, N.Y.--(BUSINESS WIRE)--Jan. 27, 2004 AngioDynamics, Inc., a wholly-owned subsidiary of E-Z-EM, Inc. (AMEX AMEX See: American Stock Exchange :EZM), today announced the launch of the new ELVS ELVS E-Learning in the Voluntary Sector ELVS Electro-Magnetic Log Voltage Simulator (TM) Procedure kit. The kit features a new 65cm sheath and a double-distal-tipped guidewire, and represents the next generation of ELVS Procedure kits. The ELVS system is a patient-friendly, minimally invasive alternative for the treatment of severe varicose veins. Current treatment options for these types of varicose veins include surgical ligation and vein stripping, invasive procedures that require an overnight hospital stay. In most cases, the entire ELVS therapy takes less than an hour to perform and visual results can be immediate. Patients who undergo the ELVS treatment can experience a rapid recovery time with no scarring, and generally can return to normal activities once they leave the doctor's office. AngioDynamics first introduced ELVS in November 2002. The new sheath will provide physicians the flexibility to treat those patients with longer refluxing vein segments. The new double-distal-tipped guidewire provides the physician a choice between a straight-tipped or j-tipped guidewire for more tortuous veins during the ELVS procedure. Commenting for AngioDynamics, David Doster, Product Manager for the ELVS Laser, said, "The 65cm ELVS Procedure kit is another example of innovation from AngioDynamics. AngioDynamics is in the business of providing solutions for vascular care, and we are committed to developing procedure kits that meet the changing needs of the ELVS System user." For additional information on the ELVS System, contact David Doster at 1-800-772-6446, ext. 126, E-mail: ddoster@angiodynamics.com, or visit the ELVS Laser web site at www.elvslaser.com. ELVS is a trademark of Biolitec, Inc. About AngioDynamics AngioDynamics, Inc. (www.angiodynamics.com) manufactures a wide range of products, including angiographic, dialysis, PTA PTA or parent-teacher association: see parent education. dilation dilation /di·la·tion/ (di-la´shun) 1. the act of dilating or stretching. 2. dilatation. di·la·tion n. 1. , thrombolytic thrombolytic /throm·bo·lyt·ic/ (throm?bo-lit´ik) dissolving or splitting up a thrombus, or an agent that so acts. thrombolytic 1. dissolving or splitting up a thrombus. 2. an agent that dissolves or splits up a thrombus. , image-guided vascular access, and endovascular laser venous system, as well as abdominal infection drainage products. AngioDynamics' focus is on therapeutic products that enable interventional physicians to treat peripheral vascular diseases and other non-coronary diseases. About E-Z-EM E-Z-EM is the world's largest manufacturer of contrast agents for gastrointestinal radiology. The Company has developed the only CT injector on the market that can help detect contrast extravasation extravasation /ex·trav·a·sa·tion/ (ek-strav?ah-za´shun) 1. a discharge or escape, as of blood, from a vessel into the tissues; blood or other substance so discharged. 2. the process of being extravasated. , the EmpowerCT(R) with patented EDA(TM) technology; it also offers a complete product set for the virtual colonoscopy practitioner. This product line consists of virtual colonoscopy hardware, software, nutritional prep kits and bowel cleaners, tagging agents and a carbon dioxide colon insufflation insufflation /in·suf·fla·tion/ (-sah-fla´shun) 1. the act of blowing a powder, vapor, or gas into a body cavity. 2. finely powdered or liquid drugs carried into the respiratory passages by such devices as aerosols. system. For additional information, please contact Tom Johnson at 1-800-544-4624, ext. 3317, E-mail: tjohnson@ezem.com, or visit our corporate web site at www.ezem.com. The statements made in this document contain certain forward-looking statements that involve a number of risks and uncertainties. Words such as "expects," "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the outcome of the Diomed patent litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. , the ability of the Company to develop its products, market acceptance of virtual colonoscopy as a new imaging procedure, market acceptance of the ELVS system, the size and quantity of orders for RSDL (Reverse Spiral Dual Layer) A technique used with dual-layer DVD discs that allows the end of the first layer to seamlessly connect to the second layer. The first layer is recorded from the inside out, and the second layer is recorded from the outside in. , future actions by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from Group Purchasing Organizations, competition, including alternative procedures which continue to replace traditional fluoroscopic Fluoroscopic (fluoroscopy) An x-ray procedure that produces immediate images and motion on a screen. The images look like those seen at airport baggage security stations. Mentioned in: Hypotonic Duodenography procedures, as well as the risk factors listed from time to time in the SEC filings of E-Z-EM, Inc., including but not limited to its Form 10-Q for the quarter ended November 29, 2003, as well as its Annual Report on Form 10-K for the year ended May 31, 2003, may affect the actual results achieved by the Company. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion